Cytogenetic, Inflammatory, Immunologic, and Infectious Basis for Dysplastic Hematopoeisis

Abstract

Myelodysplastic syndrome is a heterogeneous immunologic and epigenetic group of myeloid disorders with variable propensity for acute myelogenous leukemia (AML) conversion. Treatment is limited to growth factors, lenalidomide for 5q deletion MDS, and best supportive care for low-risk disease. Allogeneic transplantation and epigenetic therapy are conventionally considered alternatives for high-risk MDS. Inflammation, epigenetic, and cytogenetic participate in disease initiation. However, how these factors interface to develop vulnerability for the disease is largely unknown. In this review, we describe current inflammatory, immunologic, and molecular features that integrate mechanistic potential effectors for MDS.

Expression of mRNA TNFα and level of protein TNFα after exposure sCD40L in bone marrow mononuclear cells of myelodysplastic syndromes

“…According to the previous study, 40% of MDS patients have normal karyotypes, and about 10-18% have multiple karyotype disorders. It is known that abnormal karyotype is associated with poor prognosis (10,11). In this study, it seemed that most of the MDS case subjects coming to the hematology clinic were already in an advanced stage, which were consistent with the high IPSS score.…”